umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen.
Department of Oncology, Radiology, and Clinical Immunology, Section of Oncology, Uppsala University Hospital, Uppsala, Sweden. Department of Oncology, Cancer Centre Karolinska, Karolinska Hospital, Stockholm, Sweden.
Department of Oncology, Cancer Centre Karolinska, Karolinska Hospital, Stockholm, Sweden.
Department of Surgery, Huddinge University Hospital, Huddinge, Sweden.
Department of Oncology, Cancer Centre Karolinska, Karolinska Hospital, Stockholm, Sweden.
Visa övriga samt affilieringar
2002 (Engelska)Ingår i: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 62, nr 5, s. 1364-1369Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

There is scanty information on the IgG subclass response after vaccination against cancer antigens. The induction and development of the IgG subclass responses in 18 colorectal carcinoma patients vaccinated s.c. seven times with recombinant human carcinoembryonic antigen (rhCEA) over a 12-month period were analyzed by ELISA. The patients were followed for 3 years. Four rhCEA doses were used, and half of the patients also received granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant. Anti-rhCEA-specific IgG1 and IgG4 responses and, to a lesser degree, IgG2 responses were markedly enhanced by concomitant GM-CSF administration, whereas the antigen dose was of minor importance. Almost no IgG3 response was observed. A significant antibody response was noted within the first weeks for IgG1 and IgG2 but noted several months later for IgG4. The responses gradually increased by repeated immunizations and peaked around 12 months for IgG1 and a few months later for IgG2 and IgG4. A sustained but reduced response was noted for these three subclasses at 24 and 36 months. Interestingly, there was a gradual shift from a predominant IgG1 response at 6 months to an IgG4 response at 15 months. No significant change in total concentrations of the four IgG subclasses was observed comparing prevaccination concentrations with concentrations at 12 months, indicating an antigen-specific effect of GM-CSF administration on the anti-rhCEA response. The clinical significance of the individual IgG subclass antibodies for tumor response is not clear and requires additional studies.

Ort, förlag, år, upplaga, sidor
2002. Vol. 62, nr 5, s. 1364-1369
Nyckelord [en]
IgG, antibodies, myeloma, colorectal carcinoma, cancer vaccine, monoclonal antibodies, cytokine
Nationell ämneskategori
Kirurgi
Identifikatorer
URN: urn:nbn:se:umu:diva-126911PubMedID: 11888906OAI: oai:DiVA.org:umu-126911DiVA, id: diva2:1038882
Tillgänglig från: 2016-10-20 Skapad: 2016-10-20 Senast uppdaterad: 2018-06-09

Open Access i DiVA

Fulltext saknas i DiVA

PubMed

Personposter BETA

Strigård, Karin

Sök vidare i DiVA

Av författaren/redaktören
Strigård, Karin
I samma tidskrift
Cancer Research
Kirurgi

Sök vidare utanför DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetricpoäng

pubmed
urn-nbn
Totalt: 74 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf